Skip to main content
Log in

In vitro activity of azithromycin and tetracycline against 358 clinical isolates ofBrucella melitensis

  • New Antimicrobial Agents
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The in vitro activity of azithromycin against human pathogenic strains ofBrucella melitensis was tested at three centres and compared to that of tetracycline, the standard antibiotic currently used for the treatment of human brucellosis. MIC determination was carried out. Tested concentration ranges for both azithromycin and tetracycline were between 0.03 and 16 µg/ml.Brucella melitensis biotype 1, strain M16 was employed as a control microorganism. A total of 358Brucella melitensis strains from human blood cultures were tested. MIC90 (µg/ml) values ranged from 0.5 to 1.00 for azithromycin and were 0.25 for tetracycline. It was concluded that there was little difference in the sensitivity of pathogenicBrucella melitensis to azithromycin and tetracycline isolated from three different regions in Spain. These results encourage further investigations on the possible therapeutic role of azithromycin in brucellosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Landínez R, Abad R, Rodriguez Torres A: Estudio sobre el tratamiento de la brucelosis. Infectologika 1984, 5: 7–14.

    Google Scholar 

  2. Ariza J, Gudiol F, Pallares R, Rufi G, Fernandez-Viladrich P: Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrobial Agents and Chemotherapy 1985, 28: 548–551.

    PubMed  Google Scholar 

  3. Acocella G, Bertrand A, Beytout J., Duriande JB, Garcia Rodriguez JA, Kosmidis J, Micoud M, Rey M, Rodriguez Zapata M, Roux J, Stahl JP: Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. Journal of Antimicrobial Chemotherapy 1989, 23: 433–439.

    PubMed  Google Scholar 

  4. Anonymous: Azithromycin. Drugs of the Future 1988, 13: 9–12.

  5. Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 73–82.

    Google Scholar 

  6. Gladue RP, Bright GM, Isaacson RE, Newborg MF: In vitro and in vivo uptake of azithromycin by phagocytic cells: possible mechanisms of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 1989, 33: 277–282.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landínez, R., Liñares, J., Loza, E. et al. In vitro activity of azithromycin and tetracycline against 358 clinical isolates ofBrucella melitensis . Eur. J. Clin. Microbiol. Infect. Dis. 11, 265–267 (1992). https://doi.org/10.1007/BF02098096

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02098096

Keywords

Navigation